1. Home
  2. TRVG vs TSHA Comparison

TRVG vs TSHA Comparison

Compare TRVG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$5.63

Market Cap

375.4M

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.73

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
TSHA
Founded
2005
2019
Country
Germany
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.4M
1.7B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
TRVG
TSHA
Price
$5.63
$5.73
Analyst Decision
Hold
Strong Buy
Analyst Count
6
8
Target Price
$3.95
$11.63
AVG Volume (30 Days)
119.5K
4.1M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
$15.59
N/A
Revenue Next Year
$8.42
$1,152.42
P/E Ratio
$16.98
N/A
Revenue Growth
N/A
17.28
52 Week Low
$2.59
$2.53
52 Week High
$5.78
$7.30

Technical Indicators

Market Signals
Indicator
TRVG
TSHA
Relative Strength Index (RSI) 64.85 43.52
Support Level $2.78 $5.28
Resistance Level $5.70 $6.01
Average True Range (ATR) 0.34 0.45
MACD -0.04 -0.10
Stochastic Oscillator 63.38 24.09

Price Performance

Historical Comparison
TRVG
TSHA

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: